Zacks Research Has Optimistic Outlook of BDX Q3 Earnings

Becton, Dickinson and Company (NYSE:BDX) – Analysts at Zacks Research boosted their Q3 2026 earnings per share estimates for shares of Becton, Dickinson and Company in a research report issued to clients and investors on Tuesday, January 21st. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will post earnings per share of $4.02 for the quarter, up from their previous estimate of $4.01. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.42 per share.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter last year, the firm earned $3.42 EPS. Becton, Dickinson and Company’s revenue for the quarter was up 6.9% compared to the same quarter last year.

Several other equities research analysts have also issued reports on the stock. Evercore ISI lifted their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. StockNews.com lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Finally, Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price target for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Moderate Buy” and an average target price of $283.50.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $238.41 on Thursday. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $248.42. The company’s fifty day simple moving average is $227.44 and its 200-day simple moving average is $232.83. The firm has a market cap of $69.14 billion, a PE ratio of 40.24, a P/E/G ratio of 1.74 and a beta of 0.39. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th were paid a dividend of $1.04 per share. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a dividend yield of 1.74%. The ex-dividend date of this dividend was Monday, December 9th. Becton, Dickinson and Company’s payout ratio is currently 70.03%.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Roland Goette sold 4,483 shares of the stock in a transaction on Friday, December 6th. The stock was sold at an average price of $221.01, for a total transaction of $990,787.83. Following the transaction, the executive vice president now owns 24,345 shares in the company, valued at $5,380,488.45. This trade represents a 15.55 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP David Shan sold 500 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the completion of the transaction, the executive vice president now owns 5,741 shares in the company, valued at $1,377,840. This trade represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 9,844 shares of company stock valued at $2,210,716. 0.36% of the stock is owned by insiders.

Institutional Trading of Becton, Dickinson and Company

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Hantz Financial Services Inc. lifted its position in shares of Becton, Dickinson and Company by 7.2% during the 4th quarter. Hantz Financial Services Inc. now owns 66,904 shares of the medical instruments supplier’s stock valued at $15,179,000 after acquiring an additional 4,496 shares during the period. Forsta AP Fonden increased its holdings in Becton, Dickinson and Company by 1.6% in the 4th quarter. Forsta AP Fonden now owns 56,900 shares of the medical instruments supplier’s stock valued at $12,909,000 after buying an additional 900 shares during the period. Robeco Institutional Asset Management B.V. raised its position in shares of Becton, Dickinson and Company by 18.1% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 49,606 shares of the medical instruments supplier’s stock valued at $11,254,000 after buying an additional 7,593 shares in the last quarter. Patriot Financial Group Insurance Agency LLC boosted its position in shares of Becton, Dickinson and Company by 6.6% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 5,013 shares of the medical instruments supplier’s stock worth $1,137,000 after acquiring an additional 312 shares in the last quarter. Finally, Stonegate Investment Group LLC increased its stake in Becton, Dickinson and Company by 10.1% in the fourth quarter. Stonegate Investment Group LLC now owns 6,095 shares of the medical instruments supplier’s stock valued at $1,383,000 after acquiring an additional 559 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.